Ozempic Gastroparesis Lawsuit 2026: The Two Fights That Actually Decide a Semaglutide Case

Legal disclaimer: This article is for general information only and is not legal advice. Consult a licensed attorney in your state about your specific situation.

The Ozempic gastroparesis case, stated plainly

After following this litigation closely, here is my read. The Ozempic and Wegovy gastroparesis case is not won or lost on the question “did you develop gastroparesis?” That’s the price of admission. The real contest happens in two places. First: did Novo Nordisk adequately warn about the risk of stomach paralysis on its label — the failure-to-warn fight? Second: did the drug cause your gastroparesis, or did your diabetes? Miss either of those and you’ll hire the wrong lawyer or badly misjudge your own eligibility.

Semaglutide is the active ingredient in Ozempic (type 2 diabetes, U.S. launch 2017), Wegovy (obesity, 2021), and Rybelsus (oral diabetes). All three come from the Danish manufacturer Novo Nordisk. That matters, because the parallel cases against Zepbound and Mounjaro — tirzepatide, made by Eli Lilly — involve a different molecule, a different mechanism argued in court, and a different defendant. This article stays on the semaglutide side: the Novo Nordisk track.

Plenty of general GLP-1 lawsuit explainers already exist. This one goes narrow on the two features that make a semaglutide case distinct: the history of the warning label, and the diabetic-gastroparesis causation battle. Those two are exactly what separate an Ozempic case from the rest of the GLP-1 field.

---

What gastroparesis is, and why semaglutide gets blamed

Gastroparesis is a condition where the stomach’s normal muscular contractions are impaired, so food can’t move from the stomach into the small intestine on schedule — hence the nickname “stomach paralysis.” It brings chronic vomiting, early satiety, severe post-meal bloating, and abnormal weight loss. In serious cases it progresses to aspiration pneumonia, acute kidney injury from repeated vomiting, or emergency surgery.

So why point at semaglutide? Slowing gastric emptying is part of how the drug works — it’s what keeps you feeling full. That’s the crux of the plaintiffs’ argument: the same mechanism that produces the therapeutic effect can, in some patients, progress to a persistent, pathological level and produce gastroparesis, and the manufacturer knew or should have known.

One detail matters here. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. That single-versus-dual distinction splits the causation arguments and the expert-witness pools between the two drugs. An attorney who imports tirzepatide reasoning wholesale into an Ozempic case may be missing what’s specific to semaglutide.

---

The two fights that actually decide a semaglutide case

Here’s the part that separates this piece from a generic explainer. Two features define the Ozempic case, and both cut against a simple “I got hurt, therefore I win” reading.

One: the history of the warning label. U.S. Ozempic and Wegovy labels have long flagged nausea and vomiting as common side effects. But plaintiffs argue that gastroparesis as such was not adequately identified as a risk on the U.S. label when the litigation began, and reporting indicates that ileus language was added to the Ozempic label only after the drug had been on the market — around 2023. Plaintiffs build a timeline out of that: the company knew, and warned late and thinly. Novo Nordisk counters that its label met regulatory requirements and that delayed gastric emptying was a well-known property of the drug class. A large share of this case, in other words, is a documents fight over what the company knew and when it put that on the label — not about the injury itself.

Two: the diabetic-gastroparesis defense. This is the signature issue of a semaglutide case. Ozempic’s original market is type 2 diabetes patients — and diabetes is the most common cause of gastroparesis in the first place. That hands Novo Nordisk an easy line: the plaintiff’s stomach paralysis came from underlying diabetic gastroparesis, not from the drug. This confounder dispute defines the causation front for Ozempic. It’s structurally why an Ozempic-for-diabetes case is harder to prove than a tirzepatide case or a weight-loss-only case.

Understand those two and you can see why some plaintiffs have clean cases and others have uphill ones. A Wegovy-only user with no diabetes history neutralizes the second defense entirely. A longtime diabetic who took Ozempic has to clear the confounder with records showing a normal GI tract before the drug.

---

Ozempic vs. Wegovy vs. Rybelsus: same molecule, different case strength

All three are semaglutide, but they don’t sit in the same litigation position.

Product	Ingredient / indication	Causation strength / weakness
Wegovy	Semaglutide, obesity	Many users have no diabetes history — neutralizes the diabetic-gastroparesis defense, cleaner case
Ozempic	Semaglutide, type 2 diabetes	Many users are diabetic — confounder fight is unavoidable, pre-drug normal records are decisive
Rybelsus	Oral semaglutide, diabetes	Similar issues to Ozempic, plus an added question of proving exposure given oral absorption

The practical takeaway is blunt: at intake, the first thing a competent attorney establishes is which product you took, for what purpose, and starting when. A Wegovy-only plaintiff and a long-term diabetic Ozempic plaintiff get their cases built differently, even with an identical gastroparesis diagnosis.

---

Where the Novo Nordisk track sits inside MDL 3094

MDL 3094 — formally In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation — is the consolidated proceeding in the Eastern District of Pennsylvania. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, and Trulicity claims all live under it. In practice, though, it splits into two manufacturer tracks. Semaglutide cases run on the Novo Nordisk track — its own internal-document discovery, its own experts, its own arguments — separate from the Eli Lilly tirzepatide track.

Knowing the standard shape of a large pharmaceutical MDL helps you place your own case.

Stage	What happens	Rough status at publication
1. MDL formation	Similar cases transferred and consolidated	Complete (early 2024)
2. Master complaint	Consolidated pleading filed	Complete
3. Motions to dismiss	Court rules on defense challenges	Largely resolved
4. Discovery	Manufacturer internal documents and trial data produced	Ongoing
5. Expert (Daubert) hearings	Court decides which testimony is admissible	Ongoing to upcoming
6. Bellwether trials	Sample cases go before juries	Not yet set
7. Global settlement talks	Negotiations anchored to bellwether outcomes	Not underway

One institutional wrinkle worth knowing: the MDL was initially assigned to Judge Gene Pratter, who died in 2024; Judge Karen Marston succeeded her. A change of judge can shift scheduling and how the docket is managed.

---

What you have to prove, and how

The court overseeing MDL 3094 issued an order around September 2025 that effectively requires objective diagnostic proof for plaintiff eligibility. Semaglutide cases are held to that same bar.

Accepted objective evidence includes:

• Gastric emptying scintigraphy
• Breath testing
• Wireless motility capsule studies

“I kept throwing up,” on its own, is a dismissal risk. Seeing a gastroenterologist for gastric emptying studies is often something to handle before you even call a lawyer. Then comes the semaglutide-specific gate: to clear the diabetic-gastroparesis confounder, you generally want records showing your GI tract was normal before the drug (prior endoscopy or workup) plus a clean symptom-onset timeline after you started.

There’s a timing angle too. Because semaglutide has been on the market since 2017, many plaintiffs have longer exposure histories than tirzepatide users. Longer use tends to strengthen causation — but an old usage history complicates the statute-of-limitations clock discussed below.

---

Can anyone honestly give you a settlement number?

No. As of publication there is no bellwether verdict and no global settlement framework, so any specific dollar figure is speculation — and a firm leading with one is a red flag, not reassurance. What’s fair to lay out is what will drive individual payouts once a framework exists.

Factor	Effect on payout
Hospitalization or surgery history	Pushes value up
Permanent injury (e.g., bowel resection)	Pushes value up significantly
Length of use	Longer use generally strengthens causation
Pre-existing diabetes or GI conditions	Absence (Wegovy-only, etc.) helps
Objective diagnostic testing	Its absence sharply raises dismissal risk
Overlapping use of other GLP-1 drugs	Complicates causation

The Roundup litigation is the standard cautionary tale: every prediction before the first bellwether verdict was guesswork, and the settlement landscape moved sharply the moment that verdict landed. Expect the semaglutide track to follow a similar arc. This isn’t the moment to fixate on a number — it’s the moment to assess honestly where your own case is strong and weak in that table.

👉 If a mass tort’s structure is new to you, the shape of another large product case makes it click — see Philips CPAP Respironics Recall Lawsuit MDL 3014, and for how a big settlement fund gets divided, Hawaii Maui Wildfire Lawsuit 2026.

---

How to vet an attorney for a semaglutide case

There’s a real gap between a generalist personal injury firm and one with genuine semaglutide depth. Ask directly:

• Do they separate semaglutide (Ozempic/Wegovy) cases from tirzepatide (Zepbound/Mounjaro) cases in how they build strategy?
• How exactly do they plan to defeat the diabetic-gastroparesis confounder?
• Are they on, or coordinating with, the Plaintiffs’ Steering Committee for MDL 3094?
• Is their contingency rate (typically 33%–40%) and cost-deduction process spelled out in writing?
• Is the initial consultation free, with a clear process for case updates?

Fees are almost always contingency: 33%–40% of any recovery, with case costs (expert fees, records retrieval) deducted separately, and generally no fee if the case fails. Confirm the cost-deduction language in writing regardless.

👉 If you’re unsure how to weigh a free consult and what questions to bring, Lawyer Consultation Costs & Hiring Guide 2026 walks through the mechanics.

---

Common mistakes and the statute of limitations

Skipping the diagnostic workup. Without objective testing, “I kept vomiting” is a dismissal risk. Get gastric emptying studies before you talk to a lawyer if you can.

Sitting on the statute of limitations. Deadlines vary by state, and once they pass, even a clear injury loses its remedy. Semaglutide users who took the drug years ago have especially tricky start dates. The clock usually runs from the diagnosis date or the date you reasonably discovered the connection to the drug (the discovery rule) — pin that down with an attorney first.

Being vague about your diabetes history. In an Ozempic case, diabetes status is the causation hinge. Get your history straight so the attorney builds the case correctly from day one.

Signing multiple retainers. Free consults with several firms are encouraged; a formal retainer should go to one firm, chosen deliberately.

Asking for a dollar figure before evaluation. A firm quoting numbers this early is a warning sign.

If the way an MDL processes thousands of individual plaintiffs feels abstract, the mechanics are similar across mass torts. 👉 Social Media Addiction Teen Lawsuit 2026 shows how eligibility screening and consolidation work in another fast-growing MDL, and 👉 the newer Depo-Provera Brain Tumor Lawsuit 2026 is a clean example of a failure-to-warn theory built around a label timeline — the same spine as the Ozempic case.

---

What to do right now

1. Check your statute of limitations first. Note your diagnosis date and confirm your state’s deadline with an attorney.
2. Get objectively tested. If you don’t have gastric emptying scintigraphy or equivalent results, schedule a GI workup.
3. Gather your records. Pharmacy fill history, prescriptions, hospitalization and surgical records, and — for diabetic users — pre-drug GI records.
4. Consult more than one firm, for free. Prioritize firms with actual semaglutide-specific experience.
5. Sign a formal retainer with one firm, deliberately.

The semaglutide track is still early-to-mid stage — no bellwether trial, no global settlement. But your filing deadline runs regardless of where the litigation stands. If you believe you were harmed, the time to start the conversation is now.

---

This article is provided for informational purposes only and does not substitute for legal advice. Eligibility, potential settlement value, and filing deadlines can only be determined accurately through consultation with a licensed attorney in your state. Litigation status described here reflects the date of publication and may change as court orders and bellwether schedules develop — always verify current information.